-+ 0.00%
-+ 0.00%
-+ 0.00%

CytomX says FDA grants Fast Track designation for Varseta-M in relapsed/refractory metastatic colorectal cancer

PUBT·08/27/2026 12:03:26
Listen to the news
CytomX says FDA grants Fast Track designation for Varseta-M in relapsed/refractory metastatic colorectal cancer
  • CytomX received FDA Fast Track designation for Varseta-M in relapsed or refractory metastatic colorectal cancer.
  • Varseta-M is an EpCAM-targeted antibody-drug conjugate with a topoisomerase-1 inhibitor payload.
  • A potential monotherapy registrational study is planned to start in 1H 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270800PRIMZONEFULLFEED9816648) on August 27, 2026, and is solely responsible for the information contained therein.